



SIMPOSIO MULTIDISCIPLINARIO DE CÁNCER DE MAMA

POST TEXAS 2024 · ST. GALLEN 2025



11 Y 12 ABRIL 2025

UCA, Salón Juan Pablo II
Av. Alicia Moreau de Justo 1680, CABA

VIERNES 11/04

8:15 hs. PALABRAS DE BIENVENIDA

Presidentes: Dr. Claudio Martín – Dr. Francisco Terrier

Coordinadores: Dr. Facundo Argañaraz, Dra. María Eugenia Azar, Dr. Lucas Cogorno, Dr. Adrián Nervo.

8:30 hs. EDUCACIONAL ONCOLOGIA: Mind the Gap — Breast Cancer in the Youth

Moderador: Dr. Ernesto Korbenfeld

Biology of Breast Cancer in Young – Dra. Verónica Baró

Ovarian Suppression: Who, When, Why, and for How Long – Dra. Vanesa López

Survivorship - Dra. Cecilia Riggi

9:10 hs. TRABAJO ORAL MASTOLOGIA

Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: results from an international cohort study.

Dr. Santiago Acevedo

9:20 hs. TRABAJO ORAL ONCOLOGIA

OlympiA- Phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/ germline BRCA1/BRCA2 pathogenic variants & high risk HER2-negative primary breast cancer; longer term follow

Dra. Yoana Vanni

9:30 hs. DISCUSION TRABAJOS: Dr. Pablo Pérez Mesa – Dra. Diana Montoya

9:45 hs. EDUCACIONAL MASTOLOGIA: Optimizing Local Therapy

Moderador: Dr. Eduardo González

Axillary Management: When to Dissect and When to Radiate – Dra. Cristina Noblía

Defining and Avoiding Low Value Surgical Therapy – Dra. Verónica Fabiano

10:25 hs. COFFEE BREAK

10:45 hs. SIMPOSIO DE LA INDUSTRIA: NOVARTIS

"Actualizaciones Cáncer de Mama Temprano, RH+ HER2 negativo"

Disertantes: Dr. Diego Kaen – Dra. Viviana Paez



SIMPOSIO MULTIDISCIPLINARIO DE CÁNCER DE MAMA

POST TEXAS 2024 · ST. GALLEN 2025



11 Y 12 ABRIL 2025

UCA, Salón Juan Pablo II
Av. Alicia Moreau de Justo 1680, CABA

11:30 hs. **EDUCACIONAL ONCOLOGIA:** Optimizing Early HER2 Positive Breast Cancer Treatment

Moderador: Dr. Jorge Nadal

Neoadjuvant Management and Adaptive Strategies – Dr. Andrés Guercovich

Treatment of Small Tumors in Early-Stage Setting – Dra. Mariana Savignano

Post Neoadjuvant Management for non Pcr – Dr. Luciano Cermignani

12:10 hs. **TRABAJO ORAL ONCOLOGIA**

Impact of Anthracyclines in High Genomic Risk Node-Negative HR+/HER2- Breast Cancer.

Dra. Guadalupe Medina

12:20 hs. **TRABAJO ORAL MASTOLOGIA**

Early Oncologic Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS:
the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study.

Dra. Sabrina Barchuk

12:30 hs. **DISCUSION TRABAJOS:** Dr. Lucas Cogorno – Dra. Liliana Zamora

12:45 hs. **TRABAJO ORAL MASTOLOGIA**

No axillary surgery versus axillary sentinel lymph node biopsy in patients with early invasive breast cancer and breast-conserving surgery: Final primary results of the Intergroup-Sentinel-Mamma (INSEMA) trial.

Dr. Martín Loza

12:55 hs. **TRABAJO ORAL ONCOLOGIA**

Three-year event-free survival (EFS) of the multicenter phase II TRAIN-3 study evaluating image-guided optimization of neoadjuvant chemotherapy duration in stage II and III HER2-positive breast cancer (BOOG 2018-01).

Dra. Melina Winocur

13:05 hs. **DISCUSION TRABAJOS:** Dr. Enrique Díaz Cantón – Dr. Roberto Billinghurst

13:20 hs. **SIMPOSIO DE LA INDUSTRIA: ASTRAZENECA**

“Cambio de paradigma en la era del HER2LOW/Ultralow del CMm”

Disertantes: Dr. Sergio Daniele, Dra. Alejandra Maciel, Dr Guillermo Streich.



SIMPOSIO MULTIDISCIPLINARIO DE CÁNCER DE MAMA

POST TEXAS 2024 · ST. GALLEN 2025



11 Y 12 ABRIL 2025

UCA, Salón Juan Pablo II
Av. Alicia Moreau de Justo 1680, CABA

14:20 hs. TRABAJO ORAL MASTOLOGIA

Exclusive endocrine therapy or radiation therapy in women aged 70+ years with luminal-like early breast cancer (EUROPA): preplanned interim analysis of a randomized phase 3 trial.

Dr. Francisco von Stecher

14:30 hs. TRABAJO ORAL ONCOLOGIA

Imlunestrant, an Oral Selective Estrogen Receptor Degrader (SERD), as Monotherapy and Combined with Abemaciclib, for Patients w/ ER+, HER2- Advanced Breast Cancer (ABC), Pretreated w/ Endocrine Therapy (ET): Results of the Phase 3 EMBER-3 trial.

Dr. Federico Waisberg

14:40 hs. DISCUSION TRABAJOS: Dra. Adriana Borello – Dr. Juan Isetta

14:55 hs. EDUCACIONAL: PATOLOGIA

Moderadora: Dra. Alejandra Maciel

Disertante: Dra. Gabriela Acosta Haab

TILs: An Update After 10 Years of Research. Immune Biomarkers Beyond TILs

15:15 hs. EDUCACIONAL: IMÁGENES

Moderador: Dr. Daniel Msyler

Disertante: Dra. Flavia Sarquis

Risk Reduction and Early Detection: Updates on Breast Cancer Screening

- Risk-Based Screening in the Average Population
- Novel Imaging Modalities
- Screening for High-Risk Women

15:35 hs. EDUCACIONAL: RADIOTERAPIA

Moderadora: Dra. Carolina Chacón

Disertante: Dra. María Fernanda Díaz Vázquez

Does postmastectomy radiotherapy in 'intermediate-risk' breast cancer impact overall survival? 10-year results of the BIG 2-04 MRC SUPREMO trial

Ultrahypofractionated versus conventional fractionated sequential boost after whole-breast radiation therapy in breast cancer patients. One-year cosmetic outcomes of a randomized, controlled, phase 3 trial (ULTIMO trial).

16:10 hs. COFFEE BREAK



SIMPOSIO MULTIDISCIPLINARIO DE CÁNCER DE MAMA

POST TEXAS 2024 · ST. GALLEN 2025



11 Y 12 ABRIL 2025

UCA, Salón Juan Pablo II
Av. Alicia Moreau de Justo 1680, CABA

16:25 hs. **SIMPOSIO DE LA INDUSTRIA: OMICS**

RxPONDER y TAILORx: Nuevos datos para la práctica clínica. AMH y Antraciclinas

Dr. Aníbal Núñez de Pierro

17:05 hs. **EDUCACIONAL MASTOLOGIA: Prevención y calidad de vida**

Moderador: Dr. Luciano Cassab

Surgical Prevention and Management of Lymphedema – Dra. Gabriela Cimato

Obesity Related Risk for Breast Cancer – Dr. Gustavo Valiente

Sexual Health – Dra. Eugenia Renati

17:45 hs. **FIN DE LA JORNADA**

SÁBADO 12/04

8:30 hs. **CLINICAL CONTROVERSIES:** Omission of Axillary Staging in ER Positive Breast Cancer: Implications on Adjuvant Therapies

Moderadores: Dr. Gustavo Hauszpigiel – Dra. Florencia Perazzo

Omission of Axillary Staging in ER+ Disease What is The Data? – Dra. Gabriela Candás

Omission of Axillary Staging in ER+ Disease Implications for Radiotherapy. Radiation Post pCR – Dr. Andrés Rodríguez

Omission of Axillary Staging in ER+ Disease: Implications for Adjuvant Systemic Therapy – Dr. Fernando Petracchi

9:10 hs. **SIMPOSIO DE LA INDUSTRIA: RAFFO**

“Optimizando el manejo adyuvante en cáncer de mama de alto riesgo en la actualidad. Evidencia y práctica clínica”

Disertantes: Dr. Sergio Rivero y Dra. Verónica Fabiano

9:50 hs. **COFFEE BREAK**

10:00 hs. **SESIÓN INTERACTIVA: SAINT GALLEN 2025**

Primer Panel: Dres. Carola Allemand, Augusto Alva, Lisandro Benítez Gil, Andrés del Castillo, Gonzalo Gómez Abuin y Valeria Cáceres.



SIMPOSIO MULTIDISCIPLINARIO DE CÁNCER DE MAMA

POST TEXAS 2024 · ST. GALLEN 2025



11 Y 12 ABRIL 2025

UCA, Salón Juan Pablo II
Av. Alicia Moreau de Justo 1680, CABA

10.50 hs. **UPDATE REGINA – PRESENTACIÓN SUMA**

11.00 hs. Segundo Panel: Dres. Florencia Calvo, Alfredo Camargo, Dolores Mansilla, Santiago Bella, Victoria Costanzo, Vanesa Krakobsky.

12:00 hs. **PALABRAS DE CIERRE**